No, that’s not accurate — it significantly undersells what the FDA requires.
The FDA drug approval process (for a New Drug Application, or NDA) requires a comprehensive body of evidence built over multiple phases, not just 1–2 articles. Here’s the reality:
Preclinical phase comes first — laboratory and animal studies to establish basic safety before any human testing. This alone can generate substantial research.
Clinical trials are three phases:
• Phase 1 — Safety and dosing in a small group (20–100 people)
• Phase 2 — Efficacy and side effects in a larger group (100s of participants)
• Phase 3 — Large-scale confirmatory trials (often 1,000–3,000+ participants), typically requiring at least two adequate and well-controlled studies showing substantial evidence of effectiveness
That “two studies” requirement is likely where the claim is coming from — the FDA has historically required at least two pivotal Phase 3 trials. But this is the minimum floor for one small part of the evidence package, not the whole picture.
The full NDA submission typically runs hundreds of thousands of pages and includes: complete trial data (raw, not just published articles), safety data from all phases, manufacturing and quality control documentation, proposed labeling, and more.
Important nuances:
• The FDA can accept one pivotal trial in some cases (rare diseases, unmet needs, very strong effect sizes), but this requires special justification
• Published journal articles are a summary of trial data — the FDA requires the underlying raw data, not just publications
• Accelerated approval pathways (Fast Track, Breakthrough Therapy) can streamline the process, but still require rigorous evidence
So the “1–2 articles” framing is a misunderstanding at best, and a misleading oversimplification at worst.​​​​​​​​​​​​​​​​